GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study
About this item
Full title
Author / Creator
Temesgen, Zelalem , Assi, Mariam , Shweta, F N U , Vergidis, Paschalis , Rizza, Stacey A , Bauer, Philippe R , Pickering, Brian W , Razonable, Raymund R , Libertin, Claudia R , Burger, Charles D , Orenstein, Robert , Vargas, Hugo E , Palraj, Raj , Dababneh, Ala S , Chappell, Gabrielle , Chappell, Dale , Ahmed, Omar , Sakemura, Reona , Durrant, Cameron , Kenderian, Saad S and Badley, Andrew D
Publisher
England: Elsevier, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier, Inc
Subjects
More information
Scope and Contents
Contents
To assess the efficacy and safety of lenzilumab in patients with severe coronavirus disease 2019 (COVID-19) pneumonia.
Hospitalized patients with COVID-19 pneumonia and risk factors for poor outcomes were treated with lenzilumab 600 mg intravenously for three doses through an emergency single-use investigational new drug application. Patient cha...
Alternative Titles
Full title
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study
Authors, Artists and Contributors
Author / Creator
Assi, Mariam
Shweta, F N U
Vergidis, Paschalis
Rizza, Stacey A
Bauer, Philippe R
Pickering, Brian W
Razonable, Raymund R
Libertin, Claudia R
Burger, Charles D
Orenstein, Robert
Vargas, Hugo E
Palraj, Raj
Dababneh, Ala S
Chappell, Gabrielle
Chappell, Dale
Ahmed, Omar
Sakemura, Reona
Durrant, Cameron
Kenderian, Saad S
Badley, Andrew D
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7470718
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7470718
Other Identifiers
ISSN
0025-6196
E-ISSN
1942-5546
DOI
10.1016/j.mayocp.2020.08.038
